Vialox vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- Not applicable (topical; effect duration hours)
- ~7 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Twice daily
- Once weekly
- Key Benefits
- Reduces dynamic wrinkles from repetitive facial expressions
- Reversible muscle-relaxing effect without injection
- Smooths forehead, periorbital, and perioral lines
- Complementary to collagen-stimulating peptides
- Well-studied tolerability in cosmetic concentrations
- Can be combined with Syn-Ake for dual conotoxin/viper venom effect
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Generally very well-tolerated topically
- Rare contact sensitivity or mild irritation
- No clinically significant systemic neuromuscular effects at cosmetic doses
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —